<div><div></div><div><span><p><span>Altimmune entered into an underwriting agreement to sell 64.25 million shares of common stock with accompanying warrants and up to 10.75 million pre-funded warrants, at public offering prices of $3.00 per share and $2.999 per pre-funded warrant. The offering closed on Apr 24, 2026 and is expected to yield approximately $211.2 million in net proceeds. The company plans to fund Phase 3 development of pemvidutide in MASH, initiate pre-commercial activities, and for general corporate purposes.</span></p><p><strong><span>Agreement details:</span></strong></p><ul><li><strong><span>Agreement type</span></strong><span>: Underwriting agreement for public offering of common stock and warrants</span></li><li><strong><span>Counterparty</span></strong><span>: Leerink Partners and Barclays Capital, as representatives of the underwriters</span></li><li><strong><span>Signed / Effective</span></strong><span>: Apr 22 2026 / same</span></li><li><strong><span>Reason</span></strong><span>: Fund Phase 3 pemvidutide, pre-commercial work, and corporate purposes</span></li></ul><p><span>Original SEC Filing: </span>Altimmune, Inc. [ ALT ] - 8-K - Apr. 24, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

<p>Altimmune has raised approximately $211 million through an underwriting agreement to sell 64.25 million shares of common stock and up to 10.75 million pre-funded warrants, priced at $3.00 and $2.999 respectively. The offering, led by Leerink Partners and Barclays Capital, closed on April 24, 2026. The funds will support Phase 3 development of pemvidutide, pre-commercial activities, and general corporate purposes.</p>

TradingView

Altimmune

Health Care Select Sector SPDR

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

VG Health

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Barclays

Altimmune Raises ~$211 Million in Stock-and-Warrant Offering Led by Leerink and Barclays